FDA Authorizes Pfizer (PFE) -BioNTech (BNTX) COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age

Go back to FDA Authorizes Pfizer (PFE) -BioNTech (BNTX) COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age

Pfizer (PFE) Stock Rallies on Beat-and-Raise, Analysts Divided on How Shares Will React

November 2, 2021 8:44 AM EDT

Shares of Pfizer (NYSE: PFE) are trading over 3% higher in pre-open Tuesday after the company reported better-than-expected Q3 results and raised its FY guidance.

Pfizer reported EPS of $1.37 to easily beat the analyst estimate of $1.08. Revenue for the quarter came in at $24.1 billion versus the consensus estimate of $22.68 billion.

Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: More than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty(1) have come from... More

Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children Aged 5-11

October 29, 2021 5:46 PM EDT

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as 5 to... More